Pharmicell Co (005690) Fair Value & Analysis
Healthcare · KR · Market cap 671B KRW
Fair value as of: Jul 24, 2026
From 26 valuation models · updated 17 days ago
Fair value updated Jul 24, 2026, revised from 10,713 KRW to 10,648 KRW (−0.6%) since Jul 22, 2026. Share price +0.6% over the past month.
A solid business, currently priced close to our fair value.
What matters now
- The model range is unusually wide (6,968 KRW to 25,547 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 24, 2026.
How to read this chart
60‑month range 4,275 KRW – 20,250 KRW · fair‑value band 6,968 KRW – 25,547 KRW · the 11,190 KRW price screens above the 10,648 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 24, 2026.
Analysis
Pharmicell Co (005690) currently trades at 11,190 KRW, while our model-based Fair Value estimate is 10,648 KRW, implying the stock looks roughly 4.8% fairly valued today. The Quality Score stands at 70/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Trailing-twelve-month revenue stands at 23.9B KRW. Revenue declined 58.2% year over year. It earns a return on equity of -29.3%. Net debt stands at 2.3B KRW. Fundamentals as of Jul 24, 2026
Our scenario range runs from 6,968 KRW (bear case) to 25,547 KRW (bull case); at 11,190 KRW, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 47% below its 52-week high and 8% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -5%, 005690 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (19,652 KRW) versus Dividend Discount (344.05 KRW). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 24, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 78 · Market factors (momentum, volatility) 24
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells autologous drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions.
Full company description
Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells autologous drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cellgram_LC to treat hepatic insufficiency; Cellgram_ED for treating impotence; and Hearticellgram_AMI, a cardiac disease drug. It develops and produces intermediates of raw material medicines, such as nucleosides and mPEGs; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company provides Half-Serum DMEM, a cell culture medium; and PharmiSTEM culture medium for mesenchymal stem cells, as well as clinical development and commercialization services for new drugs. Further, it operates stem cell bank under Twelve brand name; and develops and sells stem cell culture media cosmetics. The company was formerly known as FcB2welve Co., Ltd and changed its name to Pharmicell Co., Ltd. in September 2011. Pharmicell Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Pharmicell Co reported revenue of 114B KRW in FY2025 versus 51.8B KRW in FY2021, a compound +21.8%/yr. Reported net income was 40.3B KRW in FY2025, compounding +43.7%/yr from FY2021.
Watch 005690: get an alert when its fair value changes →
Peer Group
Biotechnology · 603 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare Pharmicell Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Pharmicell Co (005690) overvalued or undervalued?
What is the fair value of 005690?
What is the quality score of 005690?
What is the revenue of Pharmicell Co (005690)?
What is the net profit margin of 005690?
Does Pharmicell Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Pharmicell Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.